Clinical Trials Logo

Clinical Trial Summary

The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02296684
Study type Interventional
Source Washington University School of Medicine
Contact Douglas R Adkins, M.D.
Phone 314-362-4471
Email dadkins@wustl.edu
Status Recruiting
Phase Phase 2
Start date March 25, 2015
Completion date March 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT02823574 - Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT03589339 - NBTXR3 Activated by SABR for Patients With Advanced HNSCC or NSCLC Treated With an Anti-PD1 Antibody Phase 1/Phase 2
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2
Not yet recruiting NCT03607227 - Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery Phase 4
Recruiting NCT03302676 - The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors Phase 3
Recruiting NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03688646 - Efficacy of ONS Supplementation in HNC Outpatient Under Treatment N/A
Not yet recruiting NCT02875795 - Carcinologic Speech Severity Index N/A
Recruiting NCT02308072 - Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer Phase 1
Recruiting NCT02546895 - Prospective Registration of Head and Neck Cancer
Active, not recruiting NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Completed NCT02554968 - Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer
Recruiting NCT02489084 - Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP) N/A
Active, not recruiting NCT01895829 - Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI Early Phase 1
Completed NCT01955239 - Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy N/A
Completed NCT02921984 - Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors Phase 1
Completed NCT02038114 - The Impact of a Patient Education Intervention for Ambulatory Oncology Patients N/A
Completed NCT01952821 - Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck N/A